Brodalumab: 4-Year US Pharmacovigilance Report.
Lebwohl M, Koo J, Leonardi C, Armstrong A, Rawnsley N, Goehring E, Jacobson A.
Lebwohl M, et al. Among authors: koo j.
J Drugs Dermatol. 2023 Apr 1;22(4):419-422. doi: 10.36849/JDD.7344.
J Drugs Dermatol. 2023.
PMID: 37026879
Four-year pharmacovigilance data are consistent with the established safety profile reported in long-term clinical trials and 3-year pharmacovigilance data. J Drugs Dermatol. 2023;22(4) doi:10.36849/JDD.7344 Citation: Lebwohl M, Koo J, Leonardi C, et al. Brod …
Four-year pharmacovigilance data are consistent with the established safety profile reported in long-term clinical trials and 3-year pharmac …